Global Next-Generation Immune Repertoire Sequencing Market: Overview
Profiling of T-and B-cell receptor
repertoires in an individual has led to a vast repository of information
on acquired immunity against various microorganisms. Next-generation
immune repertoire sequencing has allowed researchers to make
sophisticated immuno-bioinformatic analyses. It has generated vast
interest among the research community and biopharmaceutical industries
in the clinical development of antibody engineering, vaccine design, and
cellular immunotherapy. Rising applications of nutritional and
intestinal immunology drives the rapid evolution of the next-generation
immune repertoire sequencing. The innovative technology has provided
unprecedented insight into host–microbiome immune homeostasis, and along
with single-cell transcriptomics holds great potential in the life
sciences industries world over.
The report offers critical assessment of
the current growth outlook of the next-generation immune repertoire
sequencing market and gives insights into potential frontiers. Recent
technological advances in next-generation sequencing give an idea of
emerging investment avenues and changing competitive dynamics of key
regional markets.
Global Next-Generation Immune Repertoire Sequencing Market: Trends and Opportunities
The rising need for expanding
understanding of key processes in systems immunology is a key factor
driving the demand for next-generation immune repertoire sequencing. The
rising application of TCR repertoire sequencing in clinical settings is
one of the key aspects in improving immune repertoire sequencing. Over
the past several years, this has generated a groundswell of interest in
this high-throughput sequencing in realms of nutritional and intestinal
immunology. Its potential application in gaining insight into lymphocyte
diversity has gained some traction, catalyzing the market’s growth. For
example, next-generation immune repertoire sequencing holds enormous
potential in detecting minimal residual disease in lymphoid malignancies
post treatment. This helps in evaluating the effectiveness of
vaccination in the treatment. Furthermore, the growing role of
next-generation immune repertoire sequencing for personalized immune
modulation is a key trend boosting the next-generation immune repertoire
sequencing market.
Rising need for better anti-cancer
treatment will galvanize research into immune therapy and vaccine
development with the help of next-generation immune repertoire
sequencing. New avenues in intestinal immunology will pave way to new,
exciting avenues in the market.
Global Next-Generation Immune Repertoire Sequencing Market: Regional Outlook
On the regional front, developed regions
such as North America and Europe are expected to make great progress and
are likely to contribute substantial shares of revenue to the global
next-generation immune repertoire sequencing market. The North America
market is fueled by growing traction that immunotherapy has gained in
the treatment of cancer and infectious diseases. Developments in Europe
are expected to be driven by sizeable funding in biomedical research and
rising research in genomic and autoimmune disease.
Key Players Mentioned in the Report
The presence of several prominent players
in developed regions has raised the intensity of competition in recent
years. They are investing substantial funds on research and development
of immuno-bioinformatic analyses using next-generation immune repertoire
sequencing. Some of the key players operating in the next-generation
immune repertoire sequencing market are Adaptive Biotechnologies,
Atreca, Inc., CD Genomics, Pacific Biosciences, Juno Therapeutics, Roche
Holding AG, ArcherDX, Inc., and Illumina Inc.
No comments:
Post a Comment